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DAPT Study: Continuation of Dual Antiplatelet 
Therapy After PCI in Patients With and Without Acute 
Myocardial Infarction (MI) Beyond 1 Year Reduced 
Ischemic Events, but Increased Bleeding Compared 
With Treatment With Aspirin Alone 
Among 11,648 randomized patients (9,961 treated with 
drug-eluting stents, 1,687 with bare-metal stents), 30.7% pre-
senting with MI, between 12 and 30 months, continued thieno-
pyridine reduced stent thrombosis compared with placebo in 
patients with and without MI at presentation (MI group, 0.5% 
vs 1.9%, p<0.001; no MI group, 0.4% vs 1.1%, p<0.001). The 
reduction in major adverse cardiovascular and cerebrovascular 
events (MACCE) for continued thienopyridine was greater 
for patients with MI (3.9% vs 6.8%; p<0.001 for MI; 4.4% vs 
5.3%; p=0.08 for no MI). In both groups, continued thieno-
pyridine reduced MI (2.2% vs 5.2%, p<0.001 for MI; 2.1% 
vs 3.5%, p<0.001 for no MI) but increased bleeding (1.9% vs 
0.8%, p=0.005 for MI; 2.6% vs 1.7%, p=0.007 for no MI). 
The authors concluded that extended dual antiplatelet therapy 
reduced the risk of stent thrombosis and MI in patients with 
and without MI, but increased bleeding (Yeh RW et al, J Am 
Coll Cardiol 2015;65:2211-2221).
Metaanalysis: Dual Antiplatelet Therapy (DAPT) is 
Associated With Protection Against Stent Thrombosis 
but Increases Risk of Bleeding in Patients With Drug 
Eluting Stents (DES) / Benefit of Extended DAPT 
for Patients With First-Generation DES, but not for 
Second-Generation DES
Metaanalysis of 10 randomized controlled trials (N=32,135) 
indicated that compared to longer duration DAPT (L-DAPT; 
mean exposure time 20.3 months for second-generation DES 
and 28 months for first-generation DES), shorter duration 
DAPT (S-DAPT; mean exposure time 7.8 months for second-
generation DES and 10.9 months for first-generation DES) had 
an overall higher rate of stent thrombosis (odds ratio - OR: 
1.71; p=0.001). The effect of S-DAPT on stent thrombosis was 
attenuated with the use of second-generation DES (OR: 1.54) 
compared with first-generation DES (OR: 3.94; p for interac-
tion=0.008). S-DAPT had an overall significantly lower risk 
of bleeding (OR: 0.63; p<0.001). Finally, a numerically lower 
all-cause mortality rate was observed with S-DAPT (OR: 0.87; 
p=0.073). The authors concluded that S-DAPT had overall 
lower rates of bleeding, yet higher rates of stent thrombosis 
compared with L-DAPT; the latter effect was significantly 
attenuated with the use of second-generation DES. All-cause 
mortality was higher (not statistically) with L-DAPT (Giustino 
G et al, J Am Coll Cardiol 2015;65:1298-1310). 
ISAR-TRIPLE Trial: Antithrombotic Therapy in 
Patients with Indications for Oral Anticoagulation 
Undergoing Implantation of DES is Problematic / A 
Shorter (6-week) Course of Triple Therapy was not 
Superior to a Longer (6-Month) Course for Major 
Bleeding and Ischemic Events 
A total of 614 patients receiving concomitant aspirin and 
oral anticoagulant (OAC) were randomized to either 6-week 
(n=307) or 6-month clopidogrel therapy (n=307). The primary 
endpoint (composite of death, myocardial infarction - MI, stent 
thrombosis, stroke, or TIMI major bleeding at 9 months) oc-
curred in 30 patients (9.8%) in the 6-week group compared with 
27 patients (8.8%) in the 6-month group (hazard ratio - HR: 
1.14; p=0.63). There were no significant differences for the 
secondary combined ischemic endpoint of cardiac death, MI, 
stent thrombosis, and ischemic stroke or the secondary bleed-
ing endpoint of TIMI major bleeding. The authors concluded 
that 6 weeks of triple therapy was not superior to 6 months 
with respect to net clinical outcomes (Fiedler KA et al, J Am 
Coll Cardiol 2015; 1819-1629). 
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SYMPLICITY-3: 6-Month Negative Results of Renal 
Denervation Remain Negative at 12 Months 
The SYMPLICITY HTN-3 trial confirmed safety but not 
efficacy of renal denervation for treatment-resistant hyperten-
sion at 6 months. The 12-month results, available for 319 of 
361 denervation subjects and 48 of 101 non-crossover subjects, 
showed that in denervation subjects, the office systolic BP (SBP) 
change was greater than that observed at 6 months (−15.5±24.1 
mmHg vs −18.9±25.4 mmHg, respectively; p=0.025), but the 
24-h SBP change was not significantly different at 12 months 
(p=0.229). The non-crossover group office SBP decreased by 
−32.9±28.1 mmHg at 6 months, but this response was reduced 
to −21.4±19.9 mmHg (p=0.01) at 12 months, increasing to 
11.5±29.8 mmHg. The authors concluded that there was 
no further reduction in office or ambulatory blood pressure 
after 1-year follow-up, while there was loss of blood pressure 
reduction in the non-crossover group, probably reflecting 
decreased medication adherence (Bakris G et al, J Am Coll 
Cardiol 2015;65:1314-1321).
Low-Risk AF Patients, i.e., CHA2DS2-VASc=0 (Male), 
=1 (Female) Have a Low Risk for Stroke, Cerebral and 
Major Bleeding / With 1 Additional Stroke Risk Factor, 
i.e., CHA2DS2-VASc=1 (Male), =2 (Female), there 
is a Significant Increase in Event Rates, Including 
Mortality, if Non-anticoagulated
According with a Danish study of 39,400 patients discharged 
with diagnosis of nonvalvular atrial fibrillation (AF) with 0 or 
1 CHA2DS2-VASc risk factor, 23,572 were not treated, 5,353 
were on aspirin, and 10,475 received warfarin. Stroke event rates 
for untreated low-risk patients (CHA2DS2-VASc=0 [male], 
1 [female]) were 0.49 per 100 person-years at 1 year and 0.47 
per 100 person-years at full follow-up. Bleeding event rates 
among untreated low-risk patients were 1.08 per 100 person-
years at 1 year and 0.97 at full follow-up. The presence of 1 
additional stroke risk factor, i.e. CHA2DS2-VASc=1 (male), 
=2 (female) among untreated patients increased the stroke 
rate at 1 year to 1.55 per 100 person-years, representing a 
3-fold increase. At 1-year, bleeding increased 2.35-fold, and 
death increased 3.12-fold. The authors concluded that low-risk 
patients, i.e. CHA2DS2-VASc=0 (male), 1 (female) have a 
truly low risk for stroke and bleeding. With 1 additional stroke 
risk factor, i.e. CHA2DS2-VASc=1 (male), =2 (female), 
there was a significant increase in event rates (particularly 
mortality) if non-anticoagulated (Lip G et al, J Am Coll Cardiol 
2015;65:1385-1394).
EFFORTLESS Trial: The Subcutaneous ICD 
(S-ICD) Showed High Shock Efficacy for Ventricular 
Arrhythmias and a Decreasing Incidence of 
Inappropriate Shocks With Acceptable Complication 
Rate and Low Mortality Rate Extended at 2 Years
Among 882 patients who received a S-ICD followed for 
a mean of 2 years, arrhythmia events (n=111) were treated 
in 59 patients; 100 (90.1%) events were terminated with 1 
shock, and 109 events (98.2%) within the 5 available shocks. 
The estimated 3-year inappropriate shock rate was 13.1%, and 
all-cause mortality 4.7%, with 26 deaths (2.9%). Device-related 
complications occurred in 11.1%; there were no electrode 
failures, and no S-ICD–related endocarditis or bacteremia. 
Three devices (0.3%) were replaced for right ventricular 
pacing. The 6-month complication rate decreased by quartile 
of enrollment (Q1: 8.9%; Q4: 5.5%), and there was a trend 
toward a reduction in inappropriate shocks (Q1: 6.9% Q4: 
4.5%). The authors concluded that the S-ICD demonstrated 
high efficacy; rates of complications and inappropriate shocks 
were reduced consistently with strategic programming and as 
operator experience increased (Burke MC et al, J Am Coll 
Cardiol 2015;65:1605-1615).
Leadless Cardiac Pacemakers Exhibit Stable Electrical 
Performance Without Device-Related Adverse Events at 
1 Year in a Small Cohort of 31 Patients 
Follow-up of 31 of 33 patients (aged 76±8 years; 65% 
male) from the LEADLESS trial who received a leadless 
VVI pacemaker indicated that between 3 and 12 months of 
follow-up, there were no pacemaker-related adverse events 
reported. The pacing performance remained stable, with ad-
equate rate response observed in all (61%) patients in whom 
it was activated. The authors concluded that the leadless 
pacemaker demonstrates very stable performance and good 
safety results at 1 year (Knops RE et al, J Am Coll Cardiol 2015; 
1497-1504). 
LEGACY Study: Sustained Weight Loss Reduces 
AF Burden and Maintains Sinus Rhythm Probably 
Related to Favorable Changes in the Cardiometabolic 
Risk Factor Profile, Inflammatory State, and Cardiac 
Remodeling
Among 3 groups based on weight loss achieved (≥10%, 
3-9%, and <3%) of 355 obese (body mass index ≥27 kg/m2) 
patients with atrial fibrillation (AF), offered weight manage-
ment, AF burden and symptom severity decreased more in 
group 1 compared with groups 2 and 3 (p<0.001 for all). 
Arrhythmia-free survival regardless of rhythm or rate control 
strategies was also greatest in group 1 (p<0.001 for both). 
Weight loss and weight fluctuation were independent pre-
dictors of outcomes (p<0.001). Weight loss ≥10% resulted 
in a 6-fold (p<0.001) greater probability of arrhythmia-free 
survival. Weight fluctuation >5% partially offset this benefit, 
with a 2-fold (p=0.02) increased risk of arrhythmia recurrence. 
The authors concluded that long-term sustained weight loss is 
associated with significant reduction of AF burden and main-
tenance of sinus rhythm (Pathak RK et al, J Am Coll Cardiol 
2015;65:2159-2169). 
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German Aortic Valve Registry (GARY, 2011-2013): 
Incidence of Severe Vital Complications (SVCs) 
and Technical Procedural Complications (TCOs) 
Decreased Significantly From Year to Year, but 
Remained at ~4% With no Changes in Need for 
Sternotomy (~1.2%) and In-Hospital Death (~5%) 
Among 15,964 transcatheter aortic valve replacement 
(TAVR) procedures (mean patient age 81±6 years, 54% 
women, median logistic Euroscore I 18.3), overall in-hospital 
mortality was 5.2%, whereas SVCs occurred in 5%. Independ-
ent predictors for SVCs were female gender, pre-operative 
NYHA functional class IV, ejection fraction <30%, pre-
operative intravenous inotropes, arterial vascular disease, 
and higher degree of calcifications. TCOs occurred in 4.7% 
and decreased significantly from 2011 to 2013. An emergency 
sternotomy was performed in 1.3% of the patients. The authors 
concluded that TAVR had good outcomes and a regression 
in complications. Survival of patients who experienced SVCs 
or who required sternotomy was ~60% (Walther T et al, J Am 
Coll Cardiol 2015;65:2173-2180). 
Nordic Aortic Valve Intervention (NOTION) Trial: 
Comparing Transcatheter (TAVR) With Surgical 
Aortic Valve Replacement (SAVR) in an All-Comers 
Patient Cohort, no Significant Differences were Found 
Regarding the Primary Outcome (Death, Stroke, or 
MI) or the Exploratory Outcomes of Cardiovascular 
Mortality or Prosthesis Reintervention After 1 Year
Among 280 (mean age 79 years; 82% considered low-risk) 
patients randomized to TAVR or SAVR, no significant differ-
ence in the primary endpoint (death, stroke, or MI) was found 
(13.1% vs 16.3%). No difference in the rate of cardiovascular 
death or prosthesis reintervention was found. TAVR led to 
more pacemakers due to conduction abnormalities, larger 
improvement in effective orifice area, more total aortic valve 
regurgitation, and higher NYHA functional class at 1 year. 
SAVR patients had more major or life-threatening bleeding, 
cardiogenic shock, acute kidney injury, and new-onset or 
worsening atrial fibrillation at 30 days. The authors concluded 
that no significant difference between TAVR and SAVR was 
found for the composite rate of death from any cause, stroke, 
or MI after 1 year (Thyregod HG et al, J Am Coll Cardiol 
2015;65:2184-2194).
PRECOMBAT Study: No Difference Over 5 Years in 
MACCE Between PCI With Sirolimus Eluting Stents 
and CABG for Patients Treated for Unprotected Left 
Main Coronary Artery Stenosis
Among 600 patients with unprotected left main coronary 
artery stenosis undergoing PCI with a sirolimus-eluting stent 
(n=300) or CABG (n=300), at 5 years, the primary endpoint 
(major adverse cardiac or cerebrovascular events - MACCE: 
a composite of death from any cause, MI, stroke, or ischemia-
driven target vessel revascularization) occurred in 52 patients 
in the PCI group and 42 patients in the CABG group (event 
rates of 17.5% and 14.3%, respectively; hazard ratio - HR: 1.27; 
p=0.26). The 2 groups did not differ significantly in terms of 
death from any cause, MI, or stroke as well as their composite 
(8.4% and 9.6%; HR, 0.89; p=0.66). Ischemia-driven target 
vessel revascularization occurred more frequently in the PCI 
group than in the CABG group (11.4% and 5.5%, respec-
tively; HR: 2.11; p=0.012) (Ahn JM et al, J Am Coll Cardiol 
2015;65:2198-2206).
Therapeutic Manipulation of miRNA to Reduce 
In-Stent Restenosis / in Pig, Mouse, and in Vitro 
Models, miR-21 Promotes Vascular Inflammation and 
Remodeling After Stenting and May be a Therapeutic 
Target to Enhance Wound Healing After Vascular 
Injury
A subset of inflammatory miRNAs was documented which 
was activated after stenting in pigs, including the miR-21 
stem loop miRNAs. Genetic ablation of the miR-21 stem 
loop attenuated neointimal formation in mice post-stenting. 
This occurred via enhanced levels of anti-inflammatory M2 
macrophages coupled with an impaired sensitivity of smooth 
muscle cells to respond to vascular activation. The authors 
concluded that miR-21 plays a prominent role in promot-
ing vascular inflammation and remodeling after stent injury 
and may be a therapeutic target to enhance wound healing 
after vascular injury (McDonald RA et al, J Am Coll Cardiol 
2015;65:2314-2327). 
Meta-Analysis: Fewer Hemorrhagic Strokes, 
Cardiovascular Death, and Nonprocedural Bleeding, 
Similar All-cause Strokes or Systemic Embolism, but 
More Ischemic Strokes With LAA Closure Compared 
With Warfarin
A meta-analysis of PROTECT AF and PREVAIL trials, 
and their registries indicated that at a mean follow-up of 
2.69 years, patients receiving left atrial appendage closure 
(LAAC) with the Watchman device had fewer hemorrhagic 
strokes (hazard ratio - HR: 0.22; p=0.004), cardiovascular/ 
unexplained death (HR: 0.48; p=0.006), and nonprocedural 
bleeding (HR: 0.51; p=0.006) compared with warfarin. All-
cause stroke or systemic embolism was similar, but there were 
more ischemic strokes in the device group (HR: 1.95 and 0.22, 
respectively; p=0.05 / 0.004) (Holmes DR et al, J Am Coll 
Cardiol 2015;65:2614-2623). 
Safe Full-Body MRI in Patients With a Specifically 
Designed Implantable Cardioverter-Defibrillator 
(ICD) System: First-in-Human Randomized Study 
A total of 275 patients (76% male, age 60.4±13.8 years) 
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received an MRI-safe single- or dual-chamber ICD (Evera 
MRI ICD, Medtronic) designed for full-body imaging. Patients 
were randomly assigned 2:1 to undergo full-body MRI (MRI 
group, n=175; 1.5-T) or to undergo a 1-h waiting period with-
out MRI (control group, n=88) 9 to 12 weeks after implant. 
A subset of MRI patients underwent ventricular fibrillation 
induction testing post-MRI to characterize defibrillation func-
tion. The safety endpoint was met with 100% freedom from 
the composite endpoint (MRI-related events: occurrence of 
sustained ventricular tachyarrhythmia during MRI exposure, 
complication within 30 days related to the MRI, or loss of 
capture within 30 days of MRI; p<0.0001). A total of 34 ven-
tricular tachyarrhythmia/ventricular fibrillation episodes (20 
induced; 14 spontaneous) occurred in 24 patients post-MRI, 
with no observed effect on sensing, detection, or treatment. 
The authors concluded that this ICD system designed for full-
body MRI at 1.5-T is safe and the MRI scan does not adversely 
affect electrical performance or efficacy (Gold MR et al, J Am 
Coll Cardiol 2015;65:2581-2588).
Review & Metaanalysis: Strong Evidence  
of the Safety of Remote Monitoring (RM)  
of ICDs, with the Suggestion of a Potential  
Mortality Benefit
Data from 9 randomized controlled trials (RCTs) reporting 
clinical outcomes of 6,469 ICD patients who did (n=6,469) or 
did not undergo RM (n=3,496), indicated clinical outcomes of 
RM comparable with office follow-up for all-cause mortality 
(odds ratio - OR: 0.83; p=0.285), cardiovascular mortality 
(OR: 0.66; p=0.103), and hospitalization (OR: 0.83; p=0.196). 
However, a reduction in all-cause mortality was noted in the 3 
trials using home monitoring (OR: 0.65; p=0.021) with daily 
verification of transmission. Also the odds of inappropriate 
shock were reduced in RM patients (OR: 0.55; p=0.002) 
(Parthiban N et al, J Am Coll Cardiol 2015;65:2591-2600). 
CARDIA Study: Cumulative Blood Pressure (BP) 
Exposure in Early Adulthood Leads to Cardiac 
Dysfunction in Middle Age
At the year 25 examination of 2,479 participants, cumula-
tive BP measures were not related to LV ejection fraction; 
however, high cumulative exposure to systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) were associated with 
lower longitudinal strain rate (both p<0.001). For diastolic 
function, higher cumulative exposures to SBP and DBP were 
associated with low early diastolic longitudinal peak strain rate 
(Kishi S et al, J Am Coll Cardiol 2015;65:2679-2687). 
Digoxin Use in Registry Patients with AF had a Neutral 
Association with Outcomes Under Most Circumstances
Among 9,619 patients with atrial fibrillation (AF) and se-
rial follow-up every 6 months for up to 3 years, 2,267 (23.6%) 
received digoxin at enrollment, 681 (7.1%) during follow-up, 
and 6,671 (69.4%) never took digoxin. Digoxin use at registry 
enrollment was not associated with subsequent onset of symp-
toms, hospitalization, or mortality. Incident digoxin use during 
follow-up was not associated with subsequent death in patients 
with heart failure, but was associated with subsequent death 
in those without heart failure (hazard ratio-HR: 1.99) (Allen 
LA et al, J Am Coll Cardiol 2015;65:2691-2698).
ROCKET AF: Retrospective Analysis Indicated  
that Digoxin Treatment was Associated With a 
Significant Increase in All-Cause Mortality, Vascular 
Death, and Sudden Death in Patients With Atrial 
Fibrillation (AF)
Retrospective analysis of 5,239 (37%) out of 14,171 ran-
domly assigned patients, receiving digoxin, more likely female 
(42% vs 38%) and having a history of heart failure (73% vs 
56%), diabetes (43% vs 38%), and persistent AF (88% vs 77%; 
p<0.0001), showed that digoxin was associated with increased 
all-cause mortality (5.41 vs 4.30 events per 100 patients-years; 
hazard ratio - HR 1.17; p=0.0093), vascular death (3.55 vs 2.69 
per 100 patient-years; HR 1.19; p=0.0201), and sudden death 
(1.68 vs 1.12 events per 100 patient-years; HR 1.36; p=0.0076). 
These data indicate that a randomized trial of digoxin in treat-
ment of AF patients with and without heart failure is needed 
(Washam JB et al, Lancet 2015;385(9985):2363–2370).
TTM Trial: Comparable Cognitive Function in 
Survivors of Out-of-Hospital Cardiac Arrest After 
Target Temperature Management at 33°C vs 36°C
Among 652 cardiac arrest survivors randomized to tempera-
ture control at 33°C or 36°C, survival until 180 days after the 
arrest was 52% (33°C, n=178/328; 36°C, n=164/324). A total 
of 287 cardiac arrest survivors (33°C, n=148/36°C, n=139) 
were assessed with tests for memory, executive functions, and 
attention/mental speed and compared with a control group 
(n=119). Half of the cardiac arrest survivors had cognitive 
impairment, which was mostly mild. Cognitive outcome did not 
differ (P>0.30) between the 2 temperature groups (33°C/36°C). 
Compared with control subjects, attention/mental speed was 
more affected among cardiac arrest patients, but results for 
memory and executive functioning were similar (Lilja G et al, 
Circulation 2015;131: 1340-1349).
Some Chronic Heart Failure Patients Without Atrial 
Fibrillation (AF) are at High Risk for Stroke
Pooled data from 2 heart failure trials, the CORONA and 
the GISSI-HF, comprising 9585 patients, of whom 6054 did not 
have AF, indicated stroke occurrence in 165 patients (4.7%) 
with AF and in 206 patients (3.4%) without AF. Independent 
predictors of stroke in patients without AF included age (haz-
ard ratio-HR, 1.34 per 10 years), New York Heart Association 
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class (HR 1.60, class III/IV vs II), insulin-treated diabetes 
mellitus (1.87), body mass index (0.74, per 5 kg/m2 up to 30), 
and previous stroke (1.81). N-terminal pro B-type natriuretic 
peptide (n=2632 patients) was also an independent predictor 
of stroke (HR, 1.31; per log unit) when added to this model 
(Abdul-Rahim AH et at, Circulation 2015;131:1486-1494).
ARIC Study: Atrial Fibrillation (AF) Confers 
Increased Risk of Non–ST-Segment–Elevation 
Myocardial Infarction (NSTEMI)
The association between AF and incident MI was examined 
in 14 462 participants (mean age, 54 years; 56% women; 26% 
blacks) who were free of coronary heart disease at baseline. 
Over a median follow-up of 21.6 years, 1374 MI events oc-
curred (829 NSTEMIs, 249 STEMIs, 296 unclassifiable MIs). 
AF (n=1545) was associated with a 63% increased risk of 
MI (hazard ratio, 1.63), specifically NSTEMI (hazard ratio, 
1.80) but not STEMI (hazard ratio, 0.49; P for hazard ratio 
comparison=0.004). The association between AF and MI, total 
and NSTEMI, was stronger in women than in men (Soliman 
EZ et al, Circulation 2015;131:1843-1850).
Most Cardiotoxicity of Anthracycline Occurs Within 
the First Year and is Associated With Anthracycline 
Dose and LVEF at the End of Treatment / Early 
Detection and Prompt Therapy Appear Crucial for 
Recovery
In a cohort of 2625 patients receiving anthracycline-con-
taining therapy, cardiotoxicity occurred in 9% (n=226) at a 
median time of 3.5 months after the end of chemotherapy, 
and in 98% of cases (n=221), it occurred within the first year. 
Twenty-five (11%) patients had full and 160 (71%) partial 
recovery. End-chemotherapy LVEF (hazard ratio - HR, 1.37; 
for each percent unit decrement) and cumulative doxorubicin 
dose (HR, 1.09; for each 50 mg/m2 increment) were independ-
ent correlates of cardiotoxicity (Cardinale D et al, Circulation 
2015;131:1981-1988).
Oxygen Commonly Administered to Patients With 
STEMI May Increase Myocardial Injury Due to 
Coronary Vasoconstriction and Heightened Oxidative 
Stress
In a multicenter, prospective, randomized, controlled trial 
comparing oxygen (8 L/min) with no supplemental oxygen in 
441 patients with ST-elevation–myocardial infarction (STEMI), 
mean peak troponin was similar in the oxygen and no oxygen 
groups (57.4 vs 48.0 μg/L; ratio, 1.20; P=0.18). However, 
there was a significant increase in peak creatine kinase (1948 
vs 1543 U/L; means ratio, 1.27; P=0.01), in the rate of recur-
rent MI (5.5% vs 0.9%; P=0.006) and in frequency of cardiac 
arrhythmia (40.4% vs 31.4%; P=0.05) in the oxygen group. 
At 6 months, the oxygen group had an increase in MI size on 
cardiac magnetic resonance (n=139; 20.3 vs 13.1 g; P=0.04). 
The authors concluded that supplemental oxygen therapy in 
patients with STEMI but without hypoxia may increase early 
myocardial injury and cause larger infarct size assessed at 6 
months (Stub D et al, Circulation 2015;131:2143-2150).
STROKESTOP Study: Mass Screening in a 75-  
to 76-Year-Old Population Identifies a Significant 
Proportion (3%) of Participants With Untreated  
Atrial Fibrillation (AF)
Systematic screening using intermittent ECG recordings 
over 2 weeks among 7,173 75- to 76-year-old individuals without 
a previous diagnosis of AF uncovered 218 (3%) to have previ-
ously unknown AF, and of these, AF was found in 37 (0.5% 
of the screened population) on their first ECG. The use of 
intermittent ECGs increased new AF detection 4-fold. AF was 
previously diagnosed in 9.3% (n=666). Total AF prevalence in 
the screened population was 12.3%. Of participants with known 
AF, 149 (2.1%) had no oral anticoagulant (OAC) treatment. 
In total, 5.1% of the screened population had untreated AF; 
screening resulted in initiation of OAC treatment in 3.7%, 
with >90% of the participants with previously undiagnosed 
AF accepting initiation of OAC treatment (Svennberg E et al, 
Circulation 2015;131:2176-2184).
In Symptomatic Patients With Suspected Coronary 
Artery Disease (CAD), a Strategy of Initial Computed 
Tomography Coronary Angiography (CTA), Compared 
With Functional Testing, did not Improve Clinical 
Outcomes Over a Median of 2 Years
A total of 10,003 patients (aged 61±8) with symptoms 
suggestive of CAD (88% chest pain or dyspnea on exertion), 
and pretest likelihood of CAD 53±21%, were randomized to 
a strategy of computed tomographic coronary angiography 
(CTA) or to functional testing (exercise electrocardiography, 
nuclear stress testing, or stress echocardiography). Over me-
dian follow-up of ~2 years, a primary end-point event (death, 
myocardial infarction, hospitalization for unstable angina, 
or major procedural complication) occurred in 164 of 4996 
patients in the CTA group (3.3%) and in 151 of 5007 (3%) 
in the functional-testing group (P=NS). CTA was associated 
with fewer catheterizations showing no obstructive CAD (3.4% 
vs 4.3%, P=0.02), although more patients in the CTA group 
underwent catheterization within 90 days after randomiza-
tion (12% vs 8%). Median cumulative radiation exposure 
was lower in the CTA group (10 vs 11 mSv), but 32.6% of the 
patients in the functional-testing group had no exposure, thus 
overall exposure was higher in the CTA group (mean, 12 mSv 
vs 10 mSv; P<0.001) (Douglas PS et al, N Engl J Med 2015; 
372:1291-1300).
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TOTAL Trial: In Patients With STEMI Undergoing 
Primary PCI, Routine Manual Thrombectomy did 
not Reduce Cardiovascular Death, Recurrent MI, 
Cardiogenic Shock, or NYHA Class IV Heart Failure 
at 6 Months, But Conferred More Strokes at 1 Month
Among 10,732 patients with STEMI undergoing primary 
PCI randomized to manual thrombectomy vs PCI alone, the pri-
mary outcome (death from cardiovascular causes, recurrent MI, 
cardiogenic shock, or NYHA class IV heart failure) occurred 
in 347 of 5033 patients (6.9%) in the thrombectomy group vs 
351 of 5030 patients (7%) in the PCI-alone group (P=NS). 
The rates of cardiovascular death (3.1% vs 3.5%) and primary 
outcome plus stent thrombosis or target-vessel revasculariza-
tion (9.9% vs 9.8%) were also similar. Stroke within 30 days 
occurred in 33 patients (0.7%) in the thrombectomy group vs 
16 patients (0.3%) in the PCI-alone group (hazard ratio, 2.06; 
P=0.02) (Jolly SS et al, N Engl J Med 2015;372:1389-1398). 
Added Atrial Fibrillation (AF) Ablation to Mitral-Valve 
Surgery Led to Higher Rate of Freedom from AF at 1 
Year Among Patients With Persistent or Long-Standing 
Persistent AF, but Increased the Risk for a Permanent 
Pacemaker 
A total of 260 patients with persistent or long-standing per-
sistent AF who required mitral-valve surgery were randomized 
to undergo either concomitant surgical ablation (ablation 
group), either via pulmonary vein isolation or biatrial maze 
procedure, or no ablation (control group), all with closure of 
the left atrial appendage. More patients in the ablation group 
than in the control group were free from AF at both 6 and 
12 months (63% vs 29%, P<0.001). There was no significant 
difference between patients who underwent pulmonary-vein 
isolation and those who underwent biatrial maze procedure 
(61% and 66%). One-year mortality was 6.8% in the ablation 
group and 8.7% in the control group (P=NS). Ablation was 
associated with more implantations of a permanent pacemaker 
(21.5 vs 8.1 per 100 patient-years, P=0.01) (Gillinov AM et al, 
N Engl J Med 2015;372:1399-1409). 
OSLER Studies: Over 1 Year, Use of Evolocumab Plus 
Standard Therapy, Compared With Standard Therapy 
Alone, Reduced LDL Cholesterol and Cardiovascular 
Events
A total of 4465 patients who had completed 1 of 12 phase 
2 or 3 studies (“parent trials”) of evolocumab, were randomly 
assigned in a 2:1 ratio to receive either evolocumab (140 mg 
every 2 weeks or 420 mg monthly) plus standard therapy or 
standard therapy alone. Over 11.1 months, evolocumab re-
duced LDL cholesterol by 61%, from a median of 120 to 48 
mg/dl (P<0.001). Most adverse events occurred with similar 
frequency in the two groups, although neurocognitive events 
were reported more frequently in the evolocumab group. The 
rate of cardiovascular events at 1 year was reduced from 2.18% 
in the standard-therapy group to 0.95% in the evolocumab 
group (hazard ratio, 0.47; P=0.003) (Sabatine MS et al, N 
Engl J Med 2015;372:1500-1509). 
ODYSSEY LONG TERM Trial: Over 78 Weeks, 
Alirocumab, When Added to Statin Therapy at 
Maximum Tolerated Dose, Significantly Reduced 
LDL Cholesterol, with Evidence of Reduction in 
Cardiovascular Events With Alirocumab
A total of 2341 patients at risk for cardiovascular events 
with LDL ≥70 mg/dl (1.8 mmol/L) receiving treatment with 
statins at the maximum tolerated dose, with or without other 
lipid-lowering therapy, were randomly assigned in a 2:1 ratio to 
receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous 
injection every 2 weeks for 78 weeks. At week 24 and through 
78 weeks, the difference between the alirocumab and placebo 
groups in the mean percentage change from baseline in LDL 
cholesterol level was −62% points (P<0.001). The alirocumab 
group had higher rates of injection-site reactions (5.9% vs 
4.2%), myalgia (5.4% vs 2.9%), neurocognitive events (1.2% 
vs 0.5%), and ophthalmologic events (2.9% vs 1.9%). Major 
adverse cardiovascular events (death from coronary heart dis-
ease, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable 
angina requiring hospitalization) was lower with alirocumab 
than with placebo (1.7% vs 3.3%; hazard ratio, 0.52; P=0.02) 
(Robinson JG et al, N Engl J Med 2015;372:1489-1499).
PEGASUS-TIMI 54: In Patients with >1 Year History 
of MI, Ticagrelor Reduced the Risk of Cardiovascular 
Death, MI, or Stroke and Increased the Risk of Major 
Bleeding
Over a median of 33 months, among 21,162 patients with 
prior myocardial infarction (MI) randomized to ticagrelor 90 
mg bid or 60 mg bid, or placebo on top of low-dose aspirin, the 
two ticagrelor doses each reduced, as compared with placebo, 
the rate of the primary efficacy end point (cardiovascular 
death, MI, or stroke) to 7.85%, 7.77%, and 9.04% respectively 
(hazard ratios 0.85, P=0.008 and 0.84; P=0.004 for the two 
ticagrelor doses vs placebo). Rates of TIMI major bleeding 
were higher with ticagrelor (2.6% and 2.3%) than with placebo 
(1.06%) (P<0.001); the rates of intracranial hemorrhage or 
fatal bleeding in the three groups were 0.63%, 0.71%, and 
0.60%, respectively (Bonaca MP et al, N Engl J Med 2015; 
372:1791-1800).
STAR AF II: Addition of Linear Ablation or Ablation 
of Complex Fractionated Electrograms to Pulmonary 
Vein Isolation did not Reduce Recurrences Among 
Patients with Persistent Atrial Fibrillation (AF)
Among 589 patients with persistent AF, randomized in 
a 1:4:4 ratio to ablation with pulmonary-vein isolation (PVI) 
alone (n=67), PVI plus ablation of electrograms showing 
complex fractionated activity (n=263), or PVI plus additional 
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linear ablation across the left atrial roof and mitral valve 
isthmus (n=259), procedure time was shorter for PVI alone 
(P<0.001). At 1.5 years, 59% of patients assigned to PVI alone 
were free from recurrent AF, as compared with 49% assigned 
to PVI plus complex electrogram ablation and 46% assigned 
to PVI plus linear ablation (P=NS). There were no significant 
differences among the 3 groups for freedom from AF after 2 
ablation procedures and freedom from any atrial arrhythmia. 
Complications included tamponade (3 patients), stroke or tran-
sient ischemic attack (3 patients), and atrioesophageal fistula 
(1 patient) (Verma A et al, N Engl J Med 2015;372:1812-1822). 
THAPCA Trial: In Comatose Children Who Survived 
Out-Of-Hospital Cardiac Arrest, Therapeutic 
Normothermia is Equivalent With Therapeutic 
Hypothermia, Regarding Survival With a Good 
Functional Outcome at 1 Year
Within 6 hours after return of circulation, 295 comatose 
patients (aged 2 days to 18 years) were randomly assigned to 
therapeutic hypothermia (target temperature, 33°C) or thera-
peutic normothermia (target temperature, 36.8°C). Analysis of 
data in 260 patients indicated no significant difference in the 
primary outcome (survival at 12 months with good functional 
outcome) between the hypothermia and the normothermia 
group (20% vs 12%; relative likelihood, 1.54; P=0.14). The 
groups had similar incidences of infection and serious arrhyth-
mias, use of blood products and 28-day mortality (Moler FW 
et al, N Engl J Med 2015;372:1898-1908). 
Swedish Study: Early Cardiopulmonary Resuscitation 
(CPR) (Bystander CPR Before EMS Arrival) in Out-of-
Hospital Cardiac Arrest was Associated with a 30-Day 
Survival Rate >2-Fold Higher Than That Associated 
with no CPR Before EMS Arrival
Analysis of 30,381 witnessed out-of-hospital cardiac ar-
rests indicated that CPR was performed before the arrival of 
Emergency Medical Services (EMS) in 15,512 cases (51.1%) 
and was not performed before the arrival of EMS in 14,869 
cases (48.9%). The 30-day survival rate was 10.5% when CPR 
was performed before EMS arrival vs 4% when CPR was not 
performed before EMS arrival (P<0.001). Thus, CPR before 
the arrival of EMS was associated with an increased 30-day 
survival rate (odds ratio, 2.15) (Hasselqvist-Ax I et al, N Engl 
J Med 2015;372:2307-2315).
VADT Trial: 10-YearFollow-Up of Patients With Type 
2 Diabetes Who Had Been Randomized to Intensive 
Glucose Control for 5.6 Years Had 8.6 Fewer Major 
Cardiovascular Events per 1000 Person-Years 
Than Those Assigned to Standard Therapy, but no 
Improvement in Overall Survival
The initial VADT had shown that intensive glucose low-
ering, compared with standard therapy, did not reduce the 
rate of major cardiovascular events among 1791 military 
veterans at a median of 5.6 years. The difference in glycated 
hemoglobin levels between the 2 groups averaged 1.5% points 
during the trial and declined to 0.2 to 0.3% points by 3 years 
after the trial ended. At extended follow-up at ~10 years, the 
intensive-therapy group had a significantly lower risk of the 
primary outcome (major cardiovascular event) than did the 
standard-therapy group (hazard ratio, 0.83; P=0.04), with an 
absolute risk reduction of 8.6 major cardiovascular events 
per 1000 person-years, but did not have a reduced cardiovas-
cular mortality (hazard ratio, 0.88; P=NS). No reduction in 
total mortality was evident (Hayward RA et al, N Engl J Med 
2015;372:2197-2206).
SWIFT PRIME: Stent-Retriever Thrombectomy Within 
6 Hours, in Addition to i.v. t-PA, Improved Functional 
Outcomes at 90 Days in Stroke Due to Occlusions in the 
Proximal Anterior Intracranial Circulation
Patients (N=196) with stroke due to occlusions in the 
proximal anterior intracranial circulation, were randomized 
to thrombectomy with use of a stent retriever within 6 hours, 
in addition to intravenous t-PA (n=98), or to t-PA alone (n-
98). The study was stopped early because of efficacy. In the 
intervention group, the median time from qualifying imaging 
to groin puncture was 57 min, and the rate of substantial rep-
erfusion at the end of the procedure was 88%. Thrombectomy 
with the stent retriever plus i.v. t-PA reduced disability at 90 
days (P<0.001). The rate of functional independence was 
higher in the intervention group than in the control group 
(60% vs 35%, P<0.001). There were no significant between-
group differences in 90-day mortality (9% vs 12%, P=NS) 
or symptomatic intracranial hemorrhage (0% vs 3%, P=NS) 
(Saver JL et al, N Engl J Med 2015;372:2285-2295).
REVASCAT Trial: Anterior Circulation Stroke 
Treated Within 8 Hours After Symptom Onset, With 
Stent Retriever Thrombectomy Had Reduced Severity 
of Post-Stroke Disability and Increased Rate of 
Functional Independence
Over 2 years, 206 patients who could be treated within 8 
hours after the onset of symptoms of acute ischemic stroke 
and had confirmed proximal anterior circulation occlusion and 
absence of a large infarct on neuroimaging, were randomized 
to receive either medical therapy (including i.v. alteplase) 
and endovascular therapy with the Solitaire stent retriever 
(thrombectomy group) or medical therapy alone (control 
group). Thrombectomy reduced the severity of disability and 
led to higher rates of functional independence. At 90 days, the 
rates of intracranial hemorrhage were 1.9% in both groups, and 
rates of death 18.4% and 15.5%, respectively (P=NS) (Jovin 
TG et al, N Engl J Med 2015;372:2296-2306).
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IMPROVE-IT: Ezetimibe Added to Statin Therapy 
after Acute Coronary Syndromes Confers Incremental 
Lowering of LDL and Improved Cardiovascular 
Outcomes / Lowering LDL to Levels Below Previous 
Targets Provided Additional Benefit
A total of 18,144 patients hospitalized for acute coronary 
syndrome within the preceding 10 days and having LDL 
cholesterol levels of 50 - 100 mg/dl (1.3 to 2.6 mmol/L) if they 
were receiving lipid-lowering therapy or 50 - 125 mg/dl (1.3 to 
3.2 mmol/L) if they were not receiving lipid-lowering therapy, 
were randomized to combination of simvastatin (40 mg) and 
ezetimibe (10 mg) (simvastatin–ezetimibe) or simvastatin (40 
mg) and placebo (simvastatin monotherapy). Median LDL 
cholesterol level during the study was 53.7 mg/dl (1.4 mmol/L) 
in the simvastatin–ezetimibe group, vs 69.5 mg/dl (1.8 mmol/L) 
in the simvastatin-monotherapy group (P<0.001). The event 
rate for the primary end point (cardiovascular death, nonfatal 
MI, unstable angina requiring rehospitalization, coronary 
revascularization ≥30 days after randomization, or nonfatal 
stroke) at 7 years was 32.7% in the simvastatin–ezetimibe group 
vs 34.7% in the simvastatin-monotherapy group (hazard ratio, 
0.936; P=0.016). Rates of prespecified muscle, gallbladder, 
and hepatic adverse effects and cancer were similar in the two 
groups (Cannon CP et al, N Engl J Med 2015;372:2387-2397). 
PREPIC 2: In Patients with Severe Acute Pulmonary 
Embolism who Can be Treated with Anticoagulation, 
Use of a Retrievable Inferior Vena Cava Filter is not 
Supported as it did not Reduce the Risk of Recurrent 
Pulmonary Embolism at 3 Months
Hospitalized patients with acute, symptomatic pulmonary 
embolism associated with leg vein thrombosis and at least 1 
criterion for severity were assigned to retrievable inferior vena 
cava filter implantation plus anticoagulation (filter group; 
n=200) or anticoagulation alone with no filter implantation 
(control group; n=199). The filter was successfully inserted 
in 193 patients and was retrieved as planned in 153 of the 164 
patients. By 3 months, recurrent pulmonary embolism had 
occurred in 6 patients (3%; all fatal) in the filter group and 
in 3 patients (1.5%; 2 fatal) in the control group (P=NS). 
Results were similar at 6 months. Filter thrombosis occurred 
in 3 patients (Mismetti P et al, JAMA 2015;313:1627-1635).
Fewer than 1 in 10 Eligible Medicare Patients With 
Low Ejection Fraction (EF) Received an ICD Within 
1 Year After MI, Although ICD Implantation was 
Associated With Lower Mortality at 2 Years
According to an observational study of 10,318 Medicare 
beneficiaries with an EF of ≤35% after MI, the cumulative 
1-year ICD implantation rate was 8.1% (n=785). Patients with 
ICD implantation were more likely to have prior coronary artery 
bypass graft procedures (31% vs 20%; hazard ratio - HR, 1.49), 
higher peak troponin levels, in-hospital cardiogenic shock (13% 
vs 8%; HR, 1.57), and cardiology follow-up within 2 weeks after 
discharge (30% vs 20%; adjusted HR, 1.64) relative to patients 
who did not receive an ICD within 1 year. Implantation of ICD 
was associated with lower 2-year mortality (15.3 events per 100 
patient-years / 128 deaths in 838 patient-years vs 26.4 events 
per 100 patient-years / 3033 deaths in 11,479 patient-years; 
HR, 0.64) (Pokorney SD et al, JAMA 2015;313:2433-2440).
Bioprosthetic Mitral Valve Replacement May be a 
Reasonable Alternative to Mechanical Prosthetic Valve 
Replacement in Patients Aged 50 - 69 Years, but the 
15-Year Follow-Up in this Study is Insufficient to Fully 
Assess Lifetime Risks, Including Reoperation
Analysis of 3433 patients (aged 50-69 years) who under-
went mitral valve replacement indicated no survival difference 
between mechanical prosthetic and bioprosthetic mitral valves. 
Actuarial 15-year survival was 57.5% after mechanical vs 59.9% 
after bioprosthetic valve replacement (hazard ratio -HR, 
0.95, P=NS); the 15-year cumulative incidence of stroke was 
higher after mechanical valve replacement (65 strokes, 14% 
vs 41 strokes; 6.8%; HR, 1.62); reoperation rate was lower 
for mechanical valves (28 reoperations, 5% vs 47 reopera-
tions, 11.1%; HR, 0.59). The 15-year cumulative incidence of 
a bleeding event was higher for mechanical valves (72 events, 
14.9% vs 49 events, 9%; HR, 1.50) (Chikwe J et al, JAMA 
2015;313:1435-1442).
ENGAGE AF-TIMI 48: Edoxaban Had Greater Efficacy 
than Warfarin in Patients who were VKA Naive than 
VKA Experienced / It Also Significantly Reduced Major 
Bleeding Regardless of Prior VKA Exposure
In a subgroup of the ENGAGE AF-TIMI 48 trial which 
randomized 21,105 patients with atrial fibrillation (AF) to 
edoxaban vs warfarin, over 2.8 years, higher-dose edoxaban 
significantly reduced the risk of stroke or systemic embolism 
in patients who were vitamin K antagonist (VKA) naive (haz-
ard ratio - HR 0.71) and was similar to warfarin in the VKA 
experienced. Lower-dose edoxaban was similar to warfarin 
for stroke or systemic embolism prevention in VKA naive 
patients (HR 0.92), but was inferior to warfarin in those who 
were VKA experienced (HR 1.31; P=0.019). Both higher-dose 
and lower-dose edoxaban regimens significantly reduced the 
risk of major bleeding regardless of prior VKA experience (P 
interaction=0.90 and 0.71, respectively) (O’Donoghue ML et 
al, Eur Heart J 2015;36:1470-1477).
MATRIX: In Patients With Acute Coronary Syndrome, 
Radial Compared With Femoral Access Reduces Net 
Adverse Clinical Events, Through a Reduction in 
Major Bleeding and All-Cause Mortality
A total of 8404 patients with acute coronary syndrome, with 
or without ST-segment elevation, were randomly assigned to 
radial (4197) or femoral (4207) access for coronary angiography 
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and percutaneous coronary intervention (PCI). 369 (8.8%) 
patients with radial access had major adverse cardiovascular 
events, vs 429 (10.3%) patients with femoral access (rate ratio 
- RR 0.85; p=0.0307). 410 (9.8%) patients with radial access 
had net adverse clinical events compared with 486 (11.7%) 
patients with femoral access (0.83; p=0.0092). The difference 
was driven by major bleeding (1.6% vs 2.3%, RR 0.67; p=0.013) 
and all-cause mortality (1.6% vs 2.2%, RR 0.72; p=0.045) 
(Valgimigli M et al, Lancet 2015;385(9986):2465–2476).
PARTNER 1: Similar 5-Year Outcomes of 
Transcatheter and Surgical Aortic Valve Replacement 
for High Surgical Risk Patients With Aortic Stenosis 
The PARTNER trial has shown that mortality at 1, 2, and 
3 years of transcatheter aortic valve replacement (TAVR) is 
comparable to surgical aortic valve replacement (SAVR) for 
high-risk patients with aortic stenosis. The 5-year outcomes 
were similar. Among 3105 patients, of whom 699 were enrolled 
(348 assigned to TAVR, 351 assigned to SAVR; mean STS 
Predicted Risk of Mortality score 11.7%), at 5 years, risk of 
death was 67.8% in the TAVR group compared with 62.4% 
in the SAVR group (hazard ratio 1.04; p=NS). There was no 
structural valve deterioration requiring surgical valve replace-
ment in either group. Moderate or severe aortic regurgitation 
occurred in 40 (14%) of 280 patients in the TAVR group and 
2 (1%) of 228 in the SAVR group (p<0.0001), and was as-
sociated with increased 5-year mortality in the TAVR group 
(72.4% for moderate or severe aortic regurgitation vs 56.6% 
for mild aortic regurgitation or less; p=0.003). Thus, TAVR 
as an alternative to surgery for patients with high surgical risk 
results in similar clinical outcomes (Mack MJ et al, Lancet 
2015;385(9986):2477–2484).
5-Year Outcomes of PARTNER 1: Transcatheter 
Aortic Valve Replacement (TAVR) is More Beneficial 
Compared With Standard Treatment For Patients  
With Inoperable Aortic Stenosis 
Of 3015 patients, of whom 358 were enrolled (mean age 
83 years, STS Predicted Mortality Risk 11.7%, 54% female), 
179 were assigned to TAVR treatment and 179 were to stand-
ard treatment. 20 patients crossed over from the standard 
treatment group and 10 withdrew from study, leaving only 6 
patients at 5 years, of whom 5 had AVR treatment outside 
of the study. Mortality at 5 years was 71.8% in the TAVR 
group vs 93.6% in the standard treatment group (hazard ratio 
0.50; p<0.0001). At 5 years, 42 (86%) of 49 survivors in the 
TAVR group had NYHA class 1 or 2 symptoms compared 
with 3 (60%) of 5 in the standard treatment group. Echocar-
diography after TAVR showed durable hemodynamic benefit 
(aortic valve area 1.52 cm2 and mean gradient 10.6 mmHg at 
5 years), with no evidence of structural valve deterioration. 
Thus, TAVR is more beneficial than standard treatment for 
treatment of inoperable aortic stenosis (Kapadia SR et al, 
Lancet 2015;385(9986):2485–2491). 
HYPITAT-II Trial: for Women with Non-Severe 
Hypertensive Disorders at 34–37 Weeks of Gestation, 
Immediate Delivery Might Reduce the Already Small 
Risk of Adverse Maternal Outcomes Compared to 
Expectant Monitoring With Delivery at 37 Weeks,  
But it Increases the Risk of Neonatal Respiratory 
Distress Syndrome
Women (N=703) with non-severe hypertensive disorders of 
pregnancy between 34 and 37 weeks of gestation were randomly 
allocated to either induction of labour or caesarean section 
within 24 h (immediate delivery, 352) or a strategy aimed at 
prolonging pregnancy until 37 weeks of gestation (expectant 
monitoring, 351). The composite adverse maternal outcome 
(thromboembolic disease, pulmonary edema, eclampsia, 
HELLP syndrome, placental abruption, or maternal death), 
occurred in 4 (1.1%) women having immediate delivery vs 11 
(3.1%) women allocated to expectant monitoring (relative risk 
- RR 0.36; p=0.069). Respiratory distress syndrome was diag-
nosed in 20 (5.7%) neonates in the immediate delivery group 
vs 6 (1.7%) of 351 neonates in the expectant monitoring group 
(RR 3.3; p=0.005). No maternal or perinatal deaths occurred. 
Thus, routine immediate delivery does not seem justified and 
a strategy of expectant monitoring until the clinical situation 
deteriorates can be considered (Broekhuijsen K et al, Lancet 
2015;385(9986):2492–2501).
DENERHTN Trial: Optimum and Stepped Care 
Standardized Antihypertensive Treatment (SSAHT) 
With Renal Denervation for Resistant Hypertension 
Decreases Ambulatory Blood Pressure More Than  
the Same SSAHT Alone at 6 Months
Eligible patients aged 18–75 years received indapamide 1.5 
mg, ramipril 10 mg (or irbesartan 300 mg), and amlodipine 
10 mg daily for 4 weeks to confirm treatment resistance by 
ambulatory blood pressure monitoring. Patients (106 of 1416 
screened) were then randomly assigned (1:1) to receive either 
renal denervation plus an SSAHT regimen (renal denervation 
group, 53) or the same SSAHT alone (control group, 53). 
For SSAHT, after randomization, spironolactone 25 mg per 
day, bisoprolol 10 mg qd, prazosin 5 mg qd, and rilmenidine 
1 mg qd were sequentially added from months 2 to 5 in both 
groups if home blood pressure was ≥135/85 mmHg. The mean 
change in daytime ambulatory systolic blood pressure at 6 
months was −15.8 mmHg in the renal denervation group and 
−9.9 mmHg in the group receiving SSAHT alone, a baseline-
adjusted difference of −5.9 mmHg (−11.3 to −0.5; p=0.0329). 
The number of antihypertensive drugs and drug-adherence at 
6 months were similar between the two groups. Three minor 
renal denervation-related adverse events were noted (lumbar 
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pain in 2 patients and mild groin hematoma in 1 patient). A 
mild and similar decrease in estimated glomerular filtration 
rate from baseline to 6 months was observed in both groups. 
Thus, in patients with well defined resistant hypertension, 
renal denervation plus an SSAHT decreases ambulatory blood 
pressure more than the same SSAHT alone at 6 months (Azizi 
M et al, Lancet 2015;385(9981):1957–1965).
ROX CONTROL HTN Study: Central Arteriovenous 
(AV) Anastomosis Significantly Reduced Blood 
Pressure and Hypertensive Complications in Patients 
With Uncontrolled Hypertension
Eligible patients (83 or 43% of 195 screened) with baseline 
office systolic blood pressure of ≥140 mmHg and average 
daytime ambulatory blood pressure of ≥135/85 mmHg despite 
antihypertensive treatment were randomly assigned in a 1:1 
ratio to undergo implantation of an AV coupler device (central 
iliac AV anastomosis, 44) plus current drug treatment or to 
maintain current treatment alone (control, 39). Mean office 
systolic blood pressure reduced by 26.9±23.9 mmHg in the 
AV coupler group (p<0.0001) and by 3.7±21.2 mmHg in 
the control group (p=0.31). Mean systolic 24 h ambulatory 
blood pressure reduced by 13.5±18.8 mmHg (p<0.0001) in 
AV coupler recipients and by 0.5±15.8 mmHg (p=0.86) in 
controls. Late ipsilateral venous stenosis occurred in 12 (29%) 
of 42 patients and was treatable with venoplasty or stenting. 
Thus, this approach might be a useful adjunctive therapy for 
patients with uncontrolled hypertension (Lobo MD et al, 
Lancet 2015;385(9978):1634–1641).
Stanford University Study: Proton Pump Inhibitor 
(PPI) Usage is Associated With Increased Risk of 
Myocardial Infarction in the General Population
Via a novel “data-mining” approach for pharmacovigilance 
on multiple electronic medical record datasets and a prospec-
tively followed clinical cohort, the investigators explored the 
association of PPIs with cardiovascular risk in the general US 
population (2.9 million individuals). They found gastroesopha-
geal reflux disease (GERD) patients exposed to PPIs to have 
a 1.16 fold increased association with myocardial infarction 
(MI). Survival analysis in a prospective cohort found a two-fold 
(HR=2.00; P=0.031) increase in association with cardiovascular 
mortality. This association was independent of clopidogrel use. 
Contrariwise, H2 blockers were not associated with increased 
cardiovascular risk. The authors concluded that their findings 
support the association of PPI exposure with risk for MI in 
the general population, probably by adversely impacting vas-
cular function (Shah NH et al, PLoS One 2015;10:e0124653). 
(Editor’s note/N.B.: Some initial criticism indicates that the 
risk of PPIs, if real, is still quite small; importantly, this was 
not a prospective and not a formal epidemiological study 
evaluating known risk factors, which would have had more 
power to demonstrate a causal relationship between PPIs 
and cardiovascular disease; patients with significant GERD 
may have concomitant multiple risks of comorbid diseases 
and thus there is the possibility for stratification bias; in addi-
tion, it cannot be determined whether PPIs were prescribed 
for chest pain, thus including patients with coronary disease. 
Most clinicians still believe that the benefits of PPIs outweigh 
their risks, but further research will be needed to clarify any 
real association) (http://www.jwatch.org/fw110298/2015/06/12/
proton-pump-inhibitors-associated-with-increased-mi-risk) / 
(http://www.gastro.org/news_items/2015/6/11/interpretation-
of-study-on-ppi-heart-attack-risk).
Important Review and Other Articles
Practical management of anticoagulation in AF (Kovacs 
RJ et al, J Am Coll Cardiol 2015;65:1340-1360), Management 
of pulmonary hypertension (McLaughlin VV et al, J Am Coll 
Cardiol 2015;1976-1997), AHA/ACC/ASH Scientific Statement 
on treatment of hypertension in patients with coronary artery 
disease (Rosendorff C et al, J Am Coll Cardiol 2015;65:1998-
2038), 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus 
Statement on the Use of Percutaneous Mechanical Circula-
tory Support Devices (Rihal CS et al, J Am Coll Cardiol 
2015;65:2140-2141), Bleeding avoidance strategies during PCI 
(Singh M, J Am Coll Cardiol 2015;65:2225-2238), Functional 
tricuspid regurgitation (Dreyfus GD et al, J Am Coll Cardiol 
2015;65:2331-2336), Left atrial appendage occlusion (Alli O et 
al, J Am Coll Cardiol 2015;65:2337-2344), Cardio-pulmonary-
renal interactions (Husain-Syed F et al, J Am Coll Cardiol 
2015;65:2433-2448), Left ventricular assist devices (Mancini D 
& Colombo PC, J Am Coll Cardiol 2015;65:2542-2555), PCSK9 
inhibitors (Giugliano RP & Sabatine MS, J Am Coll Cardiol 
2015;65:2638-2651), Percutaneous interventions in aortic dis-
ease (Aranson NJ & Watkins MT, Circulation 2015;131:1291-
1299), Revised Jones criteria for rheumatic fever (Gewitz MH 
et al, Circulation 2015;131:1806-1818), Stroke prevention in 
AF (Lip G & Lane D, JAMA 2015;313:1950-1962), Acute 
stroke prevention (Prabhakaran S et al, JAMA 2015;313:1451-
1462), Statin associated muscle problems (Stroes ES et al, Eur 
Heart J 2015;36:1012-1022), Management of valvular disease 
in pregnancy (Sliwa K et al, Eur Heart J 2015;36:1078-1089).
